These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices. Malla M; Loree JM; Kasi PM; Parikh AR J Clin Oncol; 2022 Aug; 40(24):2846-2857. PubMed ID: 35839443 [TBL] [Abstract][Full Text] [Related]
23. Aberrant PRDM2 methylation as an early event in serrated lesions destined to evolve into microsatellite-instable colorectal cancers. van Toledo DE; Bleijenberg AG; Venema A; de Wit MJ; van Eeden S; Meijer GA; Carvalho B; Dekker E; Henneman P; IJspeert JE; van Noesel CJ J Pathol Clin Res; 2024 Mar; 10(2):e348. PubMed ID: 38380944 [TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 for colorectal cancer. Xu K; Yu AR; Pan SB; He J World J Gastroenterol; 2023 Sep; 29(36):5240-5253. PubMed ID: 37901447 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of commercial kits for isolation and bisulfite conversion of circulating cell-free tumor DNA from blood. Kresse SH; Brandt-Winge S; Pharo H; Flatin BTB; Jeanmougin M; Vedeld HM; Lind GE Clin Epigenetics; 2023 Sep; 15(1):151. PubMed ID: 37710283 [TBL] [Abstract][Full Text] [Related]
26. Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarcinoma. Zheng JH; Yao HF; Duan ZH; Ji PX; Yang J; Zhu YH; Jia QY; Yang JY; Liu DJ; Sun YW; Chen PC; Shi PD; Chen L Pharmaceuticals (Basel); 2022 Oct; 15(11):. PubMed ID: 36355508 [TBL] [Abstract][Full Text] [Related]
27. Roles of Methylated DNA Biomarkers in Patients with Colorectal Cancer. Ma Z; Williams M; Cheng YY; Leung WK Dis Markers; 2019; 2019():2673543. PubMed ID: 30944663 [TBL] [Abstract][Full Text] [Related]
28. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction. Nassar FJ; Msheik ZS; Nasr RR; Temraz SN Clin Epigenetics; 2021 May; 13(1):111. PubMed ID: 34001239 [TBL] [Abstract][Full Text] [Related]
29. A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer. Young GP; Pedersen SK; Mansfield S; Murray DH; Baker RT; Rabbitt P; Byrne S; Bambacas L; Hollington P; Symonds EL Cancer Med; 2016 Oct; 5(10):2763-2772. PubMed ID: 27726312 [TBL] [Abstract][Full Text] [Related]
30. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. Symonds EL; Pedersen SK; Murray D; Byrne SE; Roy A; Karapetis C; Hollington P; Rabbitt P; Jones FS; LaPointe L; Segelov E; Young GP Cancer; 2020 Apr; 126(7):1460-1469. PubMed ID: 31909823 [TBL] [Abstract][Full Text] [Related]
31. Circulating tumour DNA for monitoring colorectal cancer-a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection. Symonds EL; Pedersen SK; Murray DH; Jedi M; Byrne SE; Rabbitt P; Baker RT; Bastin D; Young GP Clin Epigenetics; 2018; 10():63. PubMed ID: 29796114 [TBL] [Abstract][Full Text] [Related]
32. Detection of methylated BCAT1 and IKZF1 after curative-intent treatment as a prognostic indicator for colorectal cancer recurrence. Pedersen SK; Symonds EL; Roy AC; Cornthwaite KJ; LaPointe LC; Young GP Cancer Med; 2023 Jan; 12(2):1319-1329. PubMed ID: 35822405 [TBL] [Abstract][Full Text] [Related]
34. Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1. Pedersen SK; Musher BL; LaPointe LC; Tuck MK; Symonds EL; Loayza N; Young GP Cancer; 2022 May; 128(10):1921-1928. PubMed ID: 35290664 [TBL] [Abstract][Full Text] [Related]